Biogenity ApS: Financial statements 2023
CVR: 39606925
Source: annual report 2023, Danish Business Authority
01/07/2022 – 30/06/2023
Biogenity ApS (CVR 39606925) has filed annual accounts for 2023. In 2023, the company reported a gross profit of DKK 2,397,327 and a net result of DKK 449,314 compared with DKK -107,560 the year before. That is an increase of 91.6% compared with the year before. Equity in the 2023 report amounted to DKK 606,762. The solvency ratio was 41%. The company had 5 employees in the financial year.
- Gross Profit
- DKK 2,397,327
- Profit/Loss
- DKK 449,314
- Equity
- DKK 606,762
- Total Assets
- DKK 1,480,715
- Employees
- 5
Development
| Year | Revenue | Gross Profit | Profit/Loss | Equity | Employees |
|---|---|---|---|---|---|
| 2023 | - | 2.4 mio. | 449 t. | 607 t. | 5 |
| 2022 | - | 1.3 mio. | -108 t. | 143 t. | 5 |
| 2021 | - | 97 t. | 117 t. | 250 t. | 3 |
| 2020 | - | -115 t. | 72 t. | 133 t. | - |
| 2019 | - | -71 t. | 141 t. | 141 t. | - |
Official annual report
Fetch this data via API
Every Danish company, financial statement and ownership record — straight into your own systems or your AI assistant via MCP.
See the API documentationAbout Biogenity ApS
Biogenity ApS is a Danish company of the type Anpartsselskab based in Aalborg Øst, founded in 2018. The company is registered under the industry Forskning og eksperimentel udvikling inden for naturvidenskab og teknik. The management consists of Kenneth Kastaniegaard and Louis Loeb. The board consists of Louis Loeb (chair) and Kenneth Kastaniegaard. The company is owned by L.Loeb Holding ApS and Kastaniegaard Holding ApS. According to the 2025 annual report, the company had an average of 4 employees. In 2025, the company reported a gross profit of DKK 1,387,873 and a net result of DKK -453,753 compared with DKK -342,877 the year before. Equity in the 2025 report amounted to DKK -189,867.